Tag Archives: Capricor Therapeutics

  1. Capricor Therapeutics Announces First Patient Treated In HOPE-Duchenne Clinical Trial

    Posted on February 22, 20161:19 pm

      CureDuchenne is pleased to see our biotech partner Capricor Therapeutics progress with their HOPE-Duchenne clinical trial. Capricor announced today the treatment of the first patient with Duchenne muscular dystrophy-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial. The patient was treated at the Cincinnati Children’s Hospital Medical Center under the direction of Read more »

  2. CureDuchenne-Funded Trial for Cardiac Therapy

    Posted on January 13, 201611:54 pm

      Capricor Therapeutics is actively recruiting participants for a clinical trial for a potential cardiac cell therapy for those with Duchenne muscular dystrophy.  CureDuchenne funded Capricor to support this trial that addresses heart disease, which is the primary cause of death for those with Duchenne.     The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a Read more »

  3. Cardiac Trial for Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy

    Posted on November 5, 20154:51 pm

      Did you know that heart failure is very common and often fatal in patients with Duchenne muscular dystrophy? The Halt cardiOmyopathy ProgrEssion in Duchenne (HOPE-Duchenne) is a clinical trial that will evaluate whether an investigational cardiac cell therapy is safe and potentially effective in minimizing scar and improving heart function in DMD associated heart Read more »

  4. Capricor Therapeutics – Webinar on Upcoming Clinical Trial for Cardiac Indication in Duchenne

    Posted on June 18, 201510:34 pm

      There has been a lot of recent Duchenne research news lately.  As a community, we are glad to see a variety of research programs moving forward with positive results. This provides hope for all those that live with Duchenne and their families. Duchenne is a complex disease and will require a variety of treatments Read more »